- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
FDA
Lilly gains panel's backing to expand Cymbalta use
August 19, 2010
Bloomberg NewsOutside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis
of studies in lower back pain and osteoarthritis of the knee.
MoreLilly's Cymbalta helps chronic pain in U.S. review
August 17, 2010
Bloomberg NewsApproval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta's
annual sales.
MoreLilly grows Alimta's sales by shrinking market
May 29, 2010
J.K. WallIn 2008, Eli Lilly and Co. asked drug regulators to change the label on Alimta so Lilly could no longer promote it as a treatment
for all patients suffering from non-small-cell lung cancer, but for only about 70 percent of the patients. Since then, sales
of the drug have accelerated, growing a whopping 48 percent last year.
MoreJudge rejects controversial Guidant plea agreement
May 8, 2010
Greg AndrewsThe deal included a $296 million criminal fine, but no charges against executives who failed to properly report problems with
the company's defibrillators.
MoreLilly sues to block copy of Evista osteoporosis drug
May 5, 2010
Bloomberg NewsWatson Pharmaceuticals filed for FDA approval to sell a low-cost version of Eli Lilly and Co.'s osteoporosis medicine. Indianapolis-based
Lilly is seeking a court order that would block approval until three of its patents expire in 2017.
MoreLilly diabetes drug may have cancer risk, FDA says
April 9, 2010
IBJ Staff and Bloomberg NewsOnce-weekly form of Byetta is awaiting the FDA's OK. Analyst predict the new version of the drug, if approved, could rack
up sales of $2 billion annually.
MoreLouisiana gets $20M in Lilly drug settlement
April 7, 2010
Associated PressLouisiana was one of 13 states that filed individual suits in state courts over allegations that Lilly pushed Zyprexa for
uses that had not been approved by federal regulators.
MoreIndiana food manufacturers ramp up safety precautions
March 20, 2010
Kathleen McLaughlinThe peanut-borne salmonella outbreak of 2009 raised awareness about the risk of illness from unlikely sources. Unfortunately,
that wasn’t the last time a seemingly innocuous ingredient made people sick, and prompted recalls.
MoreLilly sues to block generic of Adcirca lung treatment
March 17, 2010
Bloomberg NewsNetherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
MoreFDA says 'not yet' on Lilly's once-weekly Byetta
March 15, 2010
J.K. WallRegulators won't require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling,
manufacturing
processes.
MorePfizer's Viagra patent partially rejected in Lilly fight
February 16, 2010
Bloomberg NewsThe patent on impotence drug Viagra was partially rejected after the U.S. Patent and Trademark Office said it wasn't different
enough from a Chinese herb known as Horny Goat Weed. The patent was key to an infringement suit Pfizer filed in 2002 against
Eli Lilly and Co. over its rival Cialis drug.
MoreLilly shares get boost from OK of rival's drug
January 26, 2010
IBJ Staff and Bloomberg NewsShares of Lilly and partner Amylin rose on hopes that their new version of Byetta will be approved following U.S. regulators'
clearance of a similar drug.
MoreBiotech firm plans $28M Greenwood plant
January 19, 2010
Greenwood pharmaceutical firm Elona Biotechnologies plans to build a $28 million production facility and create 70 jobs to
help develop a cheaper form of insulin that could gain significant market share.
MoreFDA letters scold Lilly, others over marketing materials
January 13, 2010
Associated PressThe letter to Indianapolis-based Lilly cites a print advertisement for the antidepressant Cymbalta that did not adequately
display information about the drug's side effects.
MoreFDA cancels meeting to review Lilly's Cymbalta
January 5, 2010
Associated PressThe agency said the meeting was canceled "to allow time for the FDA to review new information" about a proposed new use for
the drug.
MoreLilly wins approval for long-acting Zyprexa
December 14, 2009
J.K. WallOnce-a-month injection of best-selling drug will have patents that could extend until 2018.
MoreLilly's Cymbalta wins new approval for anxiety disorder
November 30, 2009
J.K. WallFDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.
MoreLilly, GE announce cancer diagnostic breakthrough
October 21, 2009
J.K. WallEli Lilly and Co. and General Electric Co. say they've made a breakthrough in cancer research that could help Lilly cut the
size and cost of its clinical trials.
MorePOWER BREAKFAST: Panel applauds progress, identifies challenges
August 10, 2009
IBJ StaffA panel of five leaders of the state’s life sciences
industry took on a wide range of topics
July 24 at IBJ’s Power Breakfast
at the Westin Indianapolis.
MoreBREAKING: FDA approves Lilly blood-thinner prasugrel
July 10, 2009
J.K. WallEli Lilly and Co. finally won approval today from U.S. regulators to sell prasugrel, its highly anticipated blood thinner,
according to Bloomberg News.
MoreLilly cancer drug OK'd for new use
July 6, 2009
J.K. WallEli Lilly and Co.'s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales
of
the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer
for certain patients, Lilly announced today.
MoreCommercializing science takes too long, Cook says
May 25, 2009
Taking science from the laboratory to the commercial market takes too much time and is littered with potential pitfalls along
the way.
MoreBiotech push may help offset generic competition; some analysts skeptical
February 2, 2009
J.K. WallLilly executives want to make biotech their top focus.
MoreGeneric meds cost more than consumers realize
December 15, 2008
Generic drug makers drive up the cost of name-brand drugs developed by locally based Eli Lilly and Co. and other pharmaceutical
firms.
MoreLilly expects FDA approval of long-acting version of Zyprexa
February 4, 2008
J.K. WallEli Lilly and Co. hopes to extend the life of its best-seller Zyprexa with a potentially lucrative, long-acting form of the
antipsychotic drug. But first, the Indianapolis-based drugmaker must win over a panel of medical experts convened by the U.S.
Food and Drug Administration on Feb. 6.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Three Magi
Cats out of the bag. The object of the game is to get acquired. That means the company has no idea how to grow beyond a certain point. Email is a 1990s technology. I have laughed at this company since day one. Such a small bit player. If it was anywhere but here, it wouldn't be newsworthy.
Esther, Indy has passed Chicago in the local government corruption arena. Don't downgrade us. We're No. 1 in the Midwest.
Does the buyer get to keep the recent Accu-Chek J.D. Power award? Be careful, those Swiss cannot be trusted. Last June they pimped Mayor Ballard and former Governor Daniels at a media op, announcing plans to invest "$300 million at its Indianapolis headquarters, creating up to 100 new jobs by 2017," only to turn around and close the Roche Nutley, NJ facility and eliminate 1000 jobs there later the same week. It seems that healthcare can be innovated only as long as money is to be made. Right now Roche seems to have big eyes for China: there are many Chinese in China and potential billions in Swiss francs! Since Roche is having difficulty with US insurance companies swallowing the bill for overpriced cancer drugs (with debatable efficacy) why not sell insurance to the Chinese and market the drugs to them there? There is a name for these sort of business practices however proper decorum precludes it use in this forum.
Same kind of Luddites who oppose I-69. Guessing their 501(c)(4) application probably sailed right through the IRS.